Identification of Energy Metabolism-Related Gene Signatures From scRNA-Seq Data to Predict the Prognosis of Liver Cancer Patients

• Published in: Frontiers in cell and developmental biology Vol. 10; p. 858336
• Main Authors: Xu, Boyang, Peng, Ziqi, An, Yue, Yan, Guanyu, Yao, Xue, Guan, Lin, Sun, Mingjun
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 04.05.2022
• Subjects: Cell and Developmental Biology; energy metabolism; immune function; liver cancer; molecular subtypes; ScRNA-seq; ScRNA-seq; molecular subtypes; liver cancer; immune function; energy metabolism
• ISSN: 2296-634X; 2296-634X
• DOI: 10.3389/fcell.2022.858336

The increasingly common usage of single-cell sequencing in cancer research enables analysis of tumor development mechanisms from a wider range of perspectives. Metabolic disorders are closely associated with liver cancer development. In recent years, liver cancer has been evaluated from different perspectives and classified into different subtypes to improve targeted treatment strategies. Here, we performed an analysis of liver cancer from the perspective of energy metabolism based on single-cell sequencing data. Single-cell and bulk sequencing data of liver cancer patients were obtained from GEO and TCGA/ICGC databases, respectively. Using the Seurat R package and protocols such as consensus clustering analysis, genes associated with energy metabolism in liver cancer were identified and validated. An energy metabolism-related score (EM score) was established based on five identified genes. Finally, the sensitivity of patients in different scoring groups to different chemotherapeutic agents and immune checkpoint inhibitors was analyzed. Tumor cells from liver cancer patients were found to divide into nine clusters, with cluster 4 having the highest energy metabolism score. Based on the marker genes of this cluster and TCGA database data, the five most stable key genes (ADH4, AKR1B10, CEBPZOS, ENO1, and FOXN2) were identified as energy metabolism-related genes in liver cancer. In addition, drug sensitivity analysis showed that patients in the low EM score group were more sensitive to immune checkpoint inhibitors and chemotherapeutic agents AICAR, metformin, and methotrexate.